Atossa Genetics(ATOS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ATOS Atossa Genetics

Pre-Mkt 11-05 08:00:44 EST

2.12

-0.21

-9.01%

High2.35	Low2.10	Vol70.19K
Open2.33	D1 Closing2.33	Amplitude10.73%
Mkt Cap21.15M	Tradable Cap20.69M	Total Shares9.97M
T/O153.96K	T/O Rate0.72%	Tradable Shares9.76M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ATOS","market":"US","secType":"STK","nameCN":"Atossa Genetics","latestPrice":2.12,"timestamp":1793826000000,"preClose":2.33,"halted":0,"volume":70186,"delay":0,"changeRate":-0.09012875536480684,"floatShares":9760128,"shares":9974997,"eps":-4.342717,"marketStatus":"Pre-Mkt","change":-0.21,"latestTime":"11-05 08:00:44 EST","open":2.33,"high":2.3499,"low":2.1,"amount":153960,"amplitude":0.107253,"askPrice":2.3,"askSize":2,"bidPrice":1.94,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-4.342717,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1793889000000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":1352350800000,"exchange":"NASDAQ","adjPreClose":2.12,"postHourTrading":{"tag":"盘后","latestPrice":2.12,"preClose":2.12,"latestTime":"19:54 EST","volume":76,"amount":163.29,"timestamp":1793840058579,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.579193436651083,"impliedVol":0.6503,"impliedVolPercentile":0.1606},"requestUrl":"/m/hq/s/ATOS/tweets","defaultTab":"tweets","newsList":[{"id":"2676670685","title":"Atossa Therapeutics Staples One Contingent Value Right to Each Common Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2676670685","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2676670685?lang=en_us&edition=fundamental","pubTime":"2026-10-19 20:16","pubTimestamp":1792412177,"startTime":"0","endTime":"0","summary":"Atossa Therapeutics Staples One Contingent Value Right to Each Common ShareAtossa Therapeutics common stock will carry one stapled contingent value right (CVR) per share at the October 19, 2026, close","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261019:nNDL7mLND3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATOS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674890467","title":"Wall Street Analysts Are Bullish on Top Healthcare Picks","url":"https://stock-news.laohu8.com/highlight/detail?id=2674890467","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674890467?lang=en_us&edition=fundamental","pubTime":"2026-10-11 00:40","pubTimestamp":1791650406,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on HCW Biologics (HCWB) and Atossa Therapeutics (ATOS) ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-news-376?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-news-376?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ATOS","HCWB","LU0128526141.USD","XLV","HCSG","BK4588","LABU","XBI","BK4139","BK4581","BK4585","LU0029874061.USD","BK4539","BK4137"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674851825","title":"Atossa Therapeutics Staples CVRs to ATOS Shares Tied to Priority Review Voucher Proceeds","url":"https://stock-news.laohu8.com/highlight/detail?id=2674851825","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674851825?lang=en_us&edition=fundamental","pubTime":"2026-10-09 20:01","pubTimestamp":1791547265,"startTime":"0","endTime":"0","summary":"Atossa Therapeutics staples CVRs to ATOS shares tied to priority review voucher proceedsAtossa Therapeutics executed a stapled contingent value rights agreement, attaching one CVR to each common share","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261009:nNDL5Nttyq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ATOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674859052","title":"Atossa Therapeutics Executes Contingent Value Rights Agreement Providing Shareholders Participation in Potential Priority Review Voucher Value","url":"https://stock-news.laohu8.com/highlight/detail?id=2674859052","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674859052?lang=en_us&edition=fundamental","pubTime":"2026-10-09 20:00","pubTimestamp":1791547205,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261009:nTUA5CV1MT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ATOS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674851892","title":"Atossa Therapeutics - CVR Holders Entitled to 25% of Net Proceeds, $50 Mln Aggregate Cap","url":"https://stock-news.laohu8.com/highlight/detail?id=2674851892","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674851892?lang=en_us&edition=fundamental","pubTime":"2026-10-09 20:00","pubTimestamp":1791547205,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261009:nTUA5CV1MT:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ATOS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674590548","title":"Atossa Therapeutics - Declares One Stapled CVR Per Share as of October 19, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2674590548","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674590548?lang=en_us&edition=fundamental","pubTime":"2026-10-09 20:00","pubTimestamp":1791547205,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261009:nTUA5CV1MT:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ATOS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672753881","title":"US Research Roundup-Amrize, Dexcom, Lennar","url":"https://stock-news.laohu8.com/highlight/detail?id=2672753881","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672753881?lang=en_us&edition=fundamental","pubTime":"2026-10-01 16:24","pubTimestamp":1790843060,"startTime":"0","endTime":"0","summary":"US RESEARCH ROUNDUP-Amrize, Dexcom, LennarOct 1 (Reuters)-Wall Street securities analysts revised their ratings and price targets on several US-listed companies, including Amrize, Dexcom, and Lennar, ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261001:nL4N45N0J8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CHCO","EKG","BX","AAPL","CALM","CRH","ALB","CCL","BMRC","LIMI","ABFL","CPG.UK","IDRV","PRVT","ATOS","APPS","BAC","CI","CLX","CNTB","DOW","CAG","DAL","DT","LITP","KMX","BRO","BOH","AAPD","DKS","AIG","ADC","ALL","AMRZ","CVEO","DKNG","DRAY","BJRI","BXDC","DXCM","AAL","BANR","SPTE","ATO","CINF","DHI","CMAG","CUBI","AXGN","BANC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672273475","title":"Atossa Therapeutics : Ascendiant Capital Markets Raises Target Price to $25 from $24","url":"https://stock-news.laohu8.com/highlight/detail?id=2672273475","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672273475?lang=en_us&edition=fundamental","pubTime":"2026-10-01 13:36","pubTimestamp":1790832999,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261001:nFWN45N0HZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ATOS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671211616","title":"Atossa Therapeutics Plans Stapled CVR Issuance Tied to Potential FDA Priority Review Voucher Proceeds","url":"https://stock-news.laohu8.com/highlight/detail?id=2671211616","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671211616?lang=en_us&edition=fundamental","pubTime":"2026-09-29 20:03","pubTimestamp":1790683382,"startTime":"0","endTime":"0","summary":"Atossa Therapeutics plans stapled CVR issuance tied to potential FDA priority review voucher proceedsAtossa outlined a plan to staple one contingent value right to each ATOS share, tied to monetizing ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260929:nNDL3V5M0D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATOS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671670211","title":"Atossa Therapeutics - Shareholders to Receive One CVR Per Atos Share as of Record Date","url":"https://stock-news.laohu8.com/highlight/detail?id=2671670211","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671670211?lang=en_us&edition=fundamental","pubTime":"2026-09-29 20:00","pubTimestamp":1790683217,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260929:nTUA9QNZRM:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ATOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671211919","title":"Atossa Therapeutics - Expects to File CVR Agreement with SEC Once Executed","url":"https://stock-news.laohu8.com/highlight/detail?id=2671211919","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671211919?lang=en_us&edition=fundamental","pubTime":"2026-09-29 20:00","pubTimestamp":1790683217,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260929:nTUA9QNZRM:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ATOS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671211394","title":"Atossa Therapeutics Announces Plan to Issue Stapled CVR for Shareholders Tied to Potential Rare Pediatric Disease Priority Review Voucher","url":"https://stock-news.laohu8.com/highlight/detail?id=2671211394","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671211394?lang=en_us&edition=fundamental","pubTime":"2026-09-29 20:00","pubTimestamp":1790683217,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260929:nTUA9QNZRM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ATOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671119102","title":"Atossa Therapeutics - Cvrs Entitle Holders to 25% of Net Proceeds, Capped at $50 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2671119102","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671119102?lang=en_us&edition=fundamental","pubTime":"2026-09-29 20:00","pubTimestamp":1790683217,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260929:nTUA9QNZRM:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ATOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669689460","title":"Atossa Therapeutics CEO Steven Quay Joins ARDD 2026 Panel on Clinical Trials, Regulatory Pathways for Aging Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2669689460","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669689460?lang=en_us&edition=fundamental","pubTime":"2026-09-24 20:01","pubTimestamp":1790251299,"startTime":"0","endTime":"0","summary":"Atossa Therapeutics CEO Steven Quay joins ARDD 2026 panel on clinical trials, regulatory pathways for aging diseasesAtossa Therapeutics CEO Steven Quay will speak at ARDD 2026 at Harvard University in","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260924:nNDL7TsrGJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATOS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658931795","title":"Atossa Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2658931795","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658931795?lang=en_us&edition=fundamental","pubTime":"2026-08-10 21:31","pubTimestamp":1786368706,"startTime":"0","endTime":"0","summary":"Atossa Therapeutics Inc reports results for the quarter ended June 30 - Earnings SummaryAtossa Therapeutics IncATOS.OQreported a quarterly adjusted loss of 95 cents per share for the quarter ended Jun","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nL8N44715E:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ATOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657647159","title":"Atossa Therapeutics Inc Expected to Post a Loss of $1.08 a Share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2657647159","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657647159?lang=en_us&edition=fundamental","pubTime":"2026-08-07 23:58","pubTimestamp":1786118288,"startTime":"0","endTime":"0","summary":"Atossa Therapeutics Inc <ATOS.OQ> expected to post a loss of $1.08 a share - Earnings PreviewAtossa Therapeutics IncATOS.OQATOS.Ois expected to  show no change in quarterly revenue when it reports  re","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nL8N4441YQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ATOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657645028","title":"Atossa Therapeutics Q2 Operating Income USD -8.7 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657645028","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657645028?lang=en_us&edition=fundamental","pubTime":"2026-08-07 20:46","pubTimestamp":1786106803,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nPLXG8TN6V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ATOS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657450686","title":"Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2657450686","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657450686?lang=en_us&edition=fundamental","pubTime":"2026-08-07 20:45","pubTimestamp":1786106700,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nTUA577QVD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ATOS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657964518","title":"Atossa Therapeutics Q2 Net Loss Widens to $18.1 Million; Reports no Revenue","url":"https://stock-news.laohu8.com/highlight/detail?id=2657964518","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657964518?lang=en_us&edition=fundamental","pubTime":"2026-08-07 20:32","pubTimestamp":1786105924,"startTime":"0","endTime":"0","summary":"Atossa Therapeutics Q2 net loss widens to $18.1 million; reports no revenueAtossa Therapeutics posted a GAAP net loss of USD 18.1 million for the six months ended June 30, 2026, using USD 19.23 millio","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nNDL6966k7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATOS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655022318","title":"Atossa Therapeutics sees opportunities for (Z)-endoxifen beyond breast cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2655022318","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655022318?lang=en_us&edition=fundamental","pubTime":"2026-07-31 01:05","pubTimestamp":1785431156,"startTime":"0","endTime":"0","summary":"13:00 EDT Atossa Therapeutics (ATOS) sees opportunities for (Z)-endoxifen beyond breast cancer Published first on TheFly – the ultimate source for ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/atossa-therapeutics-sees-opportunities-for-z-endoxifen-beyond-breast-cancer-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/atossa-therapeutics-sees-opportunities-for-z-endoxifen-beyond-breast-cancer-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4079","BK4139","BK4588","ATOS","LENZ","BK4548","BK4539","Z","BK4551","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.atossatherapeutics.com;investors.atossatherapeutics.com","stockEarnings":[{"period":"1week","weight":-0.1055},{"period":"1month","weight":-0.1347},{"period":"3month","weight":-0.124},{"period":"6month","weight":-0.6214},{"period":"1year","weight":-0.8334},{"period":"ytd","weight":-0.7605}],"compareEarnings":[{"period":"1week","weight":-0.0071},{"period":"1month","weight":-0.0104},{"period":"3month","weight":-0.0023},{"period":"6month","weight":0.0396},{"period":"1year","weight":0.1356},{"period":"ytd","weight":0.1245}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines in the areas of unmet medical need in oncology. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201 for lung injury caused by cancer treatment. In addition, the company develops immunotherapy/chimeric antigen receptor therapy programs. It has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":0.269844},{"month":2,"riseRate":0.5,"avgChangeRate":0.058135},{"month":3,"riseRate":0.428571,"avgChangeRate":0.091975},{"month":4,"riseRate":0.357143,"avgChangeRate":-0.038564},{"month":5,"riseRate":0.357143,"avgChangeRate":-0.01529},{"month":6,"riseRate":0.571429,"avgChangeRate":0.074595},{"month":7,"riseRate":0.285714,"avgChangeRate":-0.09625},{"month":8,"riseRate":0.357143,"avgChangeRate":-0.039479},{"month":9,"riseRate":0.285714,"avgChangeRate":-0.037091},{"month":10,"riseRate":0.214286,"avgChangeRate":-0.162621},{"month":11,"riseRate":0.285714,"avgChangeRate":-0.052369},{"month":12,"riseRate":0.285714,"avgChangeRate":-0.125403}],"exchange":"NASDAQ","name":"Atossa Genetics","nameEN":"Atossa Genetics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.52.1","shortVersion":"4.52.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Atossa Genetics(ATOS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Atossa Genetics(ATOS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Atossa Genetics,ATOS,Atossa Genetics股票,Atossa Genetics股票老虎,Atossa Genetics股票老虎国际,Atossa Genetics行情,Atossa Genetics股票行情,Atossa Genetics股价,Atossa Genetics股市,Atossa Genetics股票价格,Atossa Genetics股票交易,Atossa Genetics股票购买,Atossa Genetics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Atossa Genetics(ATOS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Atossa Genetics(ATOS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction